Exact Sciences Corp. (NASDAQ:EXAS) Chief Financial Officer Jeffrey Thomas Elliott has recently engaged in stock transactions, according to the latest SEC filings. Elliott purchased shares worth approximately $21,224 and sold shares totaling $8,180.
On April 30, Elliott acquired additional shares of Exact Sciences through two separate transactions. The first acquisition was related to the settlement of a performance share unit award, which did not involve any monetary transaction. The second purchase involved 707 shares bought through the Employee Stock Purchase Plan at a price of $30.02 per share, amounting to a total of $21,224.
The following day, May 1, Elliott sold 136 shares of the company's stock at a price of $60.15 each. This sale, conducted under a pre-arranged 10b5-1 trading plan, was made to cover withholding taxes due upon the vesting of certain performance stock units, totaling $8,180.
Investors tracking insider transactions may note that these recent buys and sells by the CFO demonstrate active management of his holdings in the company. Post-transaction, in addition to the directly owned shares, Elliott holds a significant number of vested and unvested stock options and restricted stock units, further aligning his interests with those of the shareholders.
The transactions provide a glimpse into the financial moves of one of Exact Sciences' top executives, offering insight into how leadership is interacting with the company's stock.
InvestingPro Insights
Exact Sciences Corp. (NASDAQ:EXAS) has been navigating a challenging market, which is reflected in the company's recent stock performance and analyst expectations. According to InvestingPro Tips, the company's stock has experienced a notable decline over the last month, with a -17.89% drop in the one-month price total return as of the current year. This could signal caution to investors who are monitoring the company's short-term performance trends.
In terms of financial health, Exact Sciences appears to have a solid liquidity position. An InvestingPro Tip highlights that the company's liquid assets surpass its short-term obligations, which can provide some reassurance to investors about the company's ability to meet its immediate financial commitments.
The latest InvestingPro Data provides additional context to the company's financial state. Exact Sciences currently holds a market capitalization of $11.13 billion USD. However, the company's P/E ratio stands at a negative -53.75, and when adjusted for the last twelve months as of Q4 2023, it remains negative at -39.51, indicating that the company is not currently profitable. This aligns with an InvestingPro Tip stating that analysts do not anticipate the company will be profitable this year.
For those looking to delve deeper into the financial metrics and gain access to more InvestingPro Tips, there are 6 additional tips listed in InvestingPro for Exact Sciences. These can provide investors with a more nuanced understanding of the company's performance and potential. Remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro for further insights and analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.